Introduction to Psychedelic-Assisted Therapy (PaT) Course

Introduction to Psychedelic-assisted Therapy (PaT) Course

Step into the forefront of mental health innovation with our Introduction to Psychedelic-Assisted Therapy (PaT) Course—a vital starting point for licensed and non-licensed healthcare providers. As psychedelics gain increased recognition in mental health care, this course is your gateway to understanding and integrating these groundbreaking treatments.

Psychologists’ Association of Alberta logo

Course Info
at a Glance

Course Dates

June 4, 2024
September 3, 2024


$1,600 CAD

Live Q&A Sessions

4 Sessions Weekly on Tuesdays from 6:00 pm to 7:30 pm MST

Number of Hours

21 hours
This program is designed to be completed in 1 month

Credential(s) Earned

21 CE Credits


This course is a prerequisite for our Advanced Psychedelic-Assisted (PaT) Certification Program.

Interactive learning and community support for psychedelic therapy

This course empowers participants to confidently engage in discussions about psychedelic-assisted therapy, enabling them to answer client/patient inquiries and hold informative conversations among peers. As legislative support grows for psychedelic medicine, this course acts as a crucial bridge, equipping individuals with a foundational understanding of key psychedelics—psilocybin, MDMA, LSD, iboga, and ketamine.

14 video lessons

Dive into 14 immersive video lessons, unlocking the depths of psychedelic therapy on-demand. Learn at your pace and discover key insights to enhance your practice.

4 live Q&A sessions

Engage in real-time discussions with experts during our 4 live Q&A sessions. Get your burning questions answered and gain invaluable insights directly from industry leaders. Post-session recordings included.

30+ downloadable resources

Access over 30 downloadable resources, including guides and research papers, providing you with essential tools and knowledge for successful psychedelic therapy.

Online community

Join our thriving online community—a hub for collaboration, sharing experiences, and networking with like-minded individuals passionate about the transformative power of psychedelic therapy.

What you'll learn

View our course curriculum

This first lesson will introduce you to psychedelics and what happens when humans interact with them.  We will address the shift in stigma over the past 100 years and what has contributed to our complex relationship with psychedelics in Western society.  And we will look at the current legal access and why we need collaboration amongst physicians, therapists and practitioners to offer effective, ethical and compassionate psychedelic-assisted therapy.

Learn how the history of psychedelics is shaping this new psychedelic renaissance, and how we can avoid some of the pitfalls that occurred in the first wave of psychedelic therapy in the 60s and 70s. The depth of knowledge Dr. Erika Dyck possesses in this field is second-to-none, and her understanding of Canadian psychedelic history will shape the rest of this course work.

Providing safe and ethical psychedelic-assisted therapy is essential, not only for the most effective experience for your client, but also to protect yourself as a practitioner. You will explore ethical considerations for psychedelic assisted therapy. Covering topics around enhanced consent, making ethical decisions, and the ethics around legal access to psychedelics, these lessons will equip you with a solid foundation in the ethical practice in plant medicine.

Mushrooms, or more specifically psilocybin (the psychoactive ingredient in mushrooms), is one of the most researched psychedelics in modern medicine. This lesson will explore psilocybin’s pharmacology, indications, and effectiveness. We will also examine current psilocybin trials and studies that are being conducted, which demonstrate its healing benefits in a variety of applications.

From banned to breakthrough: MDMA’s transformation from an illicit substance to a breakthrough treatment for PTSD.  In this lesson, you will explore MDMA, what it is, how it’s best used and what MAPS has been contributing over the past decades to bring it back to legalization for therapeutic use.  This module will also cover the applications of MDMA in psychotherapy, as well as the training and preparation for facilitators and therapists to deliver this therapy most effectively.  

Ketamine is becoming the most widely used mind-altering medicine, which has extended beyond pain management into the realm of mental health applications. It is used legally and therapeutically in clinical settings in many countries, including Canada and the US. There are many indications for which it is used, employing several distinct routes of administration. The benefits, challenges, and means in which it can be incorporated into a therapist’s practice will be explored in this module.

This presentation will explore the use of LSD in the context of its therapeutic potential for the treatment of a variety of psychiatric disorders. Historical publications as well as recent anecdotal reports will be explored; both perspectives provide valuable lessons pertaining to future work with LSD.

Ibogaine is the psychoactive ingredient of Iboga, a root indigenous to Gabon in Africa. It has both traditional uses, as well as clinical applications primarily related to addiction. We will also discuss how iboga has been used to help treat individuals, including veterans and professional athletes for PTSD and Traumatic Brain Injury.

Psychedelic-assisted therapy and wellness enhancement are both areas of immense interest relating to mental health. This module will examine these areas, offer a robust discussion on how they are linked, and how they can be combined in the pursuit of attenuating our patients’ suffering and facilitating their healing. 

Since 2020, Health Canada has been approving the use of psilocybin for end-of-life distress through the Section 56 Exemption Application and more recently through the Special Access Program (SAP). Numerous clinical trials have resulted in increased awareness regarding the use of psychedelics in easing end-of-life distress in patients facing terminal illnesses; these trials have been conducted across different countries and over a span of many years, including the work of Anthony Bossis of NYU.  Dr Bossis will share from his research and clinical practice about the benefits of PaT for terminally ill patients.

For many years, Mark Haden has been involved in psychedelic-assisted therapy through MAPS Canada and other avenues. Through the combination of his vast experience and collaboration with other contributors, he has developed an in-depth manual for psychedelic therapists. Mark will share from both this manual and his personal experiences in his clinical practice and research over the past 20 years.

In this presentation, a model of psychedelic integration will be presented, focusing on the capacity for increased relational intimacy as a critical measure of post-psychedelic experience. One model describes how early trauma shapes negative beliefs about the self, others, and reality, which in turn generate inaccurate interpretations in adulthood. As a result of psychedelic therapy, these Core Unconscious Beliefs may be brought to conscious awareness for reconsideration and re-decision, which in turn creates space to evolve in relational intimacy.

Due to the unique nature of psychedelic-assisted therapy, the clinicians providing such a service have a specific set of needs in regard to preventing professional burnout. This module will begin by defining self-care and exploring professional burnout as it relates to psychedelic-assisted therapists and will proceed by exploring the unique considerations for psychedelic-assisted therapy vs. traditional psychotherapy. Additionally, tools for self-care in relation to these considerations will be examined. We will conclude by providing suggestions for aftercare practices for the psychedelic guide.

Live classes and interactive sessions

For 4 weeks, you’ll participate in interactive live Q&A sessions on Tuesdays from 6:00pm to 7:30pm Mountain Time. 

Live Q&A Sessions

Tuesdays from 6-7:30pm Mountain Time

Engage directly with your instructors and peers in our live Q&A, gaining invaluable insights and fostering a deeper understanding of the program’s key topics.

Simple, transparent pricing

ATMA provides fair and transparent pricing options, including flexible payment plans. We prioritize affordability, ensuring that our transformative therapy remains accessible to all seeking positive change.

Training for a larger team? For group rates, please get in touch with us to learn more.

$1,600 CAD

One-time payment

$600 CAD/month

3x monthly payments

$7,000 CAD

Introduction to PaT and Advanced PaT Certification Program

$5,200 CAD

Introduction to PaT and Advanced PaT Certification Program

Registration Policy

  • Commitment to Growth: All purchases are final, reflecting your commitment to personal exploration. We prepare each course with dedication, unable to offer refunds.
  • Flexibility in Learning: If your plans change, you can transfer your spot to someone else, sharing the opportunity for discovery.

Need assistance or have questions? Contact us at We’re here to ensure your journey with us is seamless and enriching.

Thank you for joining us on this journey. We look forward to supporting your exploration.

Hear what people have to say

We’re proud to support healthcare practitioners from around the world with our programs and initiatives. Learn how our students enjoyed learning with ATMA.

I loved the heart that was put into it, i.e. enthusiasm, quality content, professionalism, etc. I also appreciated my group I worked with, there were some very good conversations and sharing experiences.

Juan Jimenez

I am so grateful to have discovered this amazing program, and I am truly loving this learning platform and community. I was inspired to learn about psychedelic therapy and now I am convinced this is the field that I am meant to be in. I’m excited about bringing my unique offerings to this field and hopefully collaborating with this community along the way.

Cheryl K

This program has not only done a masterful job of setting the foundations for Psychedelic-assisted Therapy, but also helped connect participants with like-minded health providers and fostered a continued interest in exploring this needed healing modality at an even deeper level.`

Mikael Bartholdy, an ATMA psychedelic therapy course alumni

Mikael Bartholdy

The richness of the experience, expertise and discussion was deeply meaningful. Thank you ATMA.

Alison Bell

Great format of watching presentations ahead of time for the Q&A’s and then speaking to the amazing presenters about their experiences. Wonderful to connect with other therapists and interested individuals through breakout groups.

Maya Sloan

It’s wonderful to be on live Zoom calls with so many amazing teachers. Thank you all, so much gratitude for this space!

Karolina Mikos

Meet your instructors

Featuring a number of leading experts

Anthony Bossis, PhD, Clinical Assistant Professor, Department of Psychiatry NYU, ATMA psychedelic therapy training instructor in Canada

Dr. Anthony Bossis

PhD, Clinical Assistant Professor, Department of Psychiatry NYU
Devon Christie, Clinical Instructor, UBC, Family Physician, , ATMA psychedelic therapy training instructor in Canada

Dr. Devon Christie

MD, CCFP, RTC (Relational Somatic Therapy)
Mark Haden, VP of Clearmind Medicine, Adjunct Prof., UBC, ATMA psychedelic therapy training instructor in Canada

Mark Haden

MSW, Qi Integrated Health - Clinical Supervisor, Adjunct Professor - UBC
Mike Mathers, Addictions and Trauma Therapist, ATMA psychedelic therapy training instructor in Canada

Mike Mathers

M.Sc., M.A., R.C.C., Addictions and Trauma Therapist

Bruce Sanguin

Psychotherapist, Clinical Fellow at CAMFT

Erika Dyck

Prof. & Canadian Research Chair, USask
Trevor Millar, Board Member, Canadian Psychedelic Association, ATMA psychedelic therapy training instructor in Canada

Trevor Millar

Ambio Live Sciences Inc. - Co-Founder, Ibogaine Facilitator

Saundra Jain

MA, PsyD, LPC, Psychotherapist

Taunya Craig

Rachel Dundas

Registered Psychologist

Natalie Bergstrom

ATMA VP of Programming

Ready to get started?

Begin your training with us today and take your practice to the next level, helping to shape the future of mental health care.


Questions about our Introduction to PaT Course?

Please reach out to us via phone or email if your question is not addressed on this page.

This course is designed to help practicing social workers, counsellors, psychologists, psychiatrists, medical practitioners, and non-licensed health care providers gain a basic understanding of psychedelic therapy through evidence-based tools and information. This course is a prerequisite for those looking to enroll into our Advanced PaT Certification Program 

This course is facilitated entirely online so you can participate from anywhere in the world. We include weekly live Q&A sessions with leading experts to provide valuable information and face-to-face community building. Our Advanced PaT Certification Program includes an in-person portion.

ATMA’s Introduction to PsychedelicAssisted Therapy course is a prerequisite to ATMA’s Advanced PaT Certification Program. If you have participated in an equivalent PaT training course, you can request an exemption by filling out the Intro course exemption form HERE: 

Participants will receive a Certificate of Completion stating the 21 hours completed and can be utilized to claim CE credits with many organizations. ATMA is currently working on CE Accreditation with the Canadian Psychological Association (CPA). If you require assistance, please contact us. 

ATMA is not offering scholarships at this time. Any future updates will be listed on the website. 

All ATMA programs and courses are non-refundable. If your situation changes, contact us to discuss.